Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TARS

Tarsus Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for TARS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.06

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 18:19 UTC.

What Tarsus Pharmaceuticals, Inc. does

The company is a biopharmaceutical firm focused on developing and commercializing eye care therapeutics. It launched XDEMVY, an FDA-approved treatment for Demodex blepharitis caused by mite infestation, after completing multiple clinical trials that demonstrated the drug was well tolerated and met primary endpoints. The company is expanding XDEMVY's potential uses to treat related eye conditions and is investigating other formulations of its active ingredient, lotilaner, for conditions including ocular rosacea and infectious diseases.

Summarized from Tarsus Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.06
Debt/equity0.21

Revenue, margins & earnings

FY2021: net loss $14M on revenue $57M$57MFY2021FY2022: net loss $62M on revenue $26M$26MFY2022FY2023: net loss $136M on revenue $17M$17MFY2023FY2024: net loss $116M on revenue $183M$183MFY2024FY2025: net loss $66M on revenue $451M$451MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-17
  • 2026-09-17DirectorSale-66$5.3K
  • 2026-09-17DirectorOption exercise201—
  • 2026-09-17DirectorRestricted Stock UnitsOption exercise-302—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Tarsus Pharmaceuticals, Inc. do?

The company is a biopharmaceutical firm focused on developing and commercializing eye care therapeutics.

When did TARS last file with the SEC?

Tarsus Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-13. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 18:19 UTC. This page is also available as JSON at /api/data?ticker=TARS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TARS and 5,000+ tickers.

Create a free account — keep TARS
For your agent
GET /api/data?ticker=TARS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt